On Tuesday, Taysha Gene Therapies Inc (NASDAQ: TSHA) was 2.08% up from the session before settling in for the closing price of $5.05. A 52-week range for TSHA has been $1.05 – $5.40.
A company in the Healthcare sector has dropped its sales by -63.99% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 3.63%. With a float of $222.28 million, this company’s outstanding shares have now reached $272.73 million.
Taysha Gene Therapies Inc (TSHA) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Taysha Gene Therapies Inc stocks. The insider ownership of Taysha Gene Therapies Inc is 18.52%, while institutional ownership is 87.00%. The most recent insider transaction that took place on Sep 22 ’25, was worth 30,479. Before that another transaction happened on Sep 10 ’25, when Company’s President and Head of R&D sold 200,000 for $3.23, making the entire transaction worth $646,000. This insider now owns 1,006,439 shares in total.
Taysha Gene Therapies Inc (TSHA) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.07 earnings per share (EPS) during the time that was better than consensus figure (set at -0.09) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.63% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.54% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
You can see what Taysha Gene Therapies Inc (TSHA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 12.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 173.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.43 in one year’s time.
